Cargando…

Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Kalogirou, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300850/ https://www.ncbi.nlm.nih.gov/pubmed/30581509 http://dx.doi.org/10.5114/pg.2018.79815

Ejemplares similares

Lean non-alcoholic fatty liver disease: do not forget diabetes
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Hepatitis C virus infection and atherosclerotic cardiovascular disease: recent knowledge, further insights
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2020)

Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Sexual dysfunction among women with systemic lupus erythematosus: might it reflect cardiovascular disease burden?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Non-alcoholic fatty liver disease, diabetes medications and blood pressure
por: Ilias, Ioannis, et al.
Publicado: (2021)

Meckel’s diverticulum complications in three first-degree relatives: time to rethink familial predisposition?
por: Patoulias, Ioannis, et al.
Publicado: (2020)

Body Composition and Non-alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2016)

Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2018)

The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
por: Pokharel, Arbinda, et al.
Publicado: (2021)

Eyeing non-alcoholic fatty liver disease: The noninvasive way
por: Gude, Dilip
Publicado: (2011)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Growing challenge of post-liver transplantation non-alcoholic fatty liver disease
por: Kalogirou, Maria Styliani, et al.
Publicado: (2022)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum
por: Liu, Qianjiao, et al.
Publicado: (2021)

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
por: Jeong, Seogsong, et al.
Publicado: (2023)

Serum chemerin in patients with rheumatoid arthritis: can it unravel the Chimera of concomitant type 2 diabetes?
por: Patoulias, Dimitrios Ioannis
Publicado: (2020)

miRNA-122: Can it unravel an alternative pathway in early diagnosis and prognosis of type 2 diabetes mellitus?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Multipronged Approach to Assess Risk Factors for Non-alcoholic Fatty Liver Disease
por: Hidrus, Aizuddin, et al.
Publicado: (2022)

Translation Research in Molecular Disease Diagnosis: Bridging Gap from Laboratory to Practice
por: Mishra, Pradyumna K, et al.
Publicado: (2011)

Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?
por: Patoulias, Dimitrios
Publicado: (2021)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Comments on Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran
por: Karimi-Sari, H., et al.
Publicado: (2017)

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
por: Abbas, Tahany, et al.
Publicado: (2020)

Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease
por: Liu, Dong, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies
por: Lu, Li-Yu, et al.
Publicado: (2022)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
por: Tang, Xue, et al.
Publicado: (2022)

MATWIN: bridging the gap between academic research and industry
por: Reiffers, Josy, et al.
Publicado: (2015)

Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Role of empagliflozin in chronic lithium toxicity
por: Dyson, Vicki
Publicado: (2022)

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
por: Jeong, Seogsong, et al.
Publicado: (2022)

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Bridging the epilepsy treatment gap in low- and middle-income nations
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2016)

Antidementia drug use in Japan: Bridging the research‐to‐practice gap
por: Okumura, Yasuyuki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_46n7biittogu4vnao4ldaruoh2